Bausch Health Companies (BHC) Canada Announces Expanded Availability of CABTREO Gel

Bausch Health Companies Inc. (NYSE:BHC) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 9, Bausch Health Companies Inc. (NYSE:BHC), Canada, announced the availability of CABTREO gel 1.2% w/w, 0.15% w/w, and 3.1% w/w to beneficiaries of the public drug plans of Nova Scotia and Ontario.

The gel, which treats acne vulgaris, would also be available through the federal government’s Non-Insured Health Benefits drug plan for Indigenous populations and that of the Correctional Service of Canada.

CABTREO treats acne vulgaris in patients aged 12 and older, and is the first and only triple-combination topical treatment for acne that is approved by Health Canada. It has three action mechanisms as an antibiotic, a retinoid, and an antibacterial agent.

Bausch Health Companies Inc. (NYSE:BHC) develops, manufactures, and markets a range of generic, branded, and branded generic pharmaceuticals, over-the-counter products, and medical devices. The company operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb.

While we acknowledge the potential of BHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.